Instrument selection for the ASAS core outcome set for axial spondyloarthritis
Issued Date
2023-06-01
Resource Type
ISSN
00034967
eISSN
14682060
Scopus ID
2-s2.0-85132403417
Pubmed ID
35680390
Journal Title
Annals of the Rheumatic Diseases
Volume
82
Issue
6
Start Page
763
End Page
772
Rights Holder(s)
SCOPUS
Bibliographic Citation
Annals of the Rheumatic Diseases Vol.82 No.6 (2023) , 763-772
Suggested Citation
Navarro-Compán V., Boel A., Boonen A., Mease P.J., Dougados M., Kiltz U., Landewé R.B.M., Baraliakos X., Bautista-Molano W., Chiowchanwisawakit P., Dagfinrud H., Fallon L., Garrido-Cumbrera M., Gensler L., Elzorkany B.K., Haroon N., Kwan Y.H., MacHado P.M., Maksymowych W., Molto A., De Peyrecave N., Poddubnyy D., Protopopov M., Ramiro S., Song I.H., Van Weely S., Van Der Heijde D. Instrument selection for the ASAS core outcome set for axial spondyloarthritis. Annals of the Rheumatic Diseases Vol.82 No.6 (2023) , 763-772. 772. doi:10.1136/annrheumdis-2022-222747 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/83489
Title
Instrument selection for the ASAS core outcome set for axial spondyloarthritis
Author(s)
Navarro-Compán V.
Boel A.
Boonen A.
Mease P.J.
Dougados M.
Kiltz U.
Landewé R.B.M.
Baraliakos X.
Bautista-Molano W.
Chiowchanwisawakit P.
Dagfinrud H.
Fallon L.
Garrido-Cumbrera M.
Gensler L.
Elzorkany B.K.
Haroon N.
Kwan Y.H.
MacHado P.M.
Maksymowych W.
Molto A.
De Peyrecave N.
Poddubnyy D.
Protopopov M.
Ramiro S.
Song I.H.
Van Weely S.
Van Der Heijde D.
Boel A.
Boonen A.
Mease P.J.
Dougados M.
Kiltz U.
Landewé R.B.M.
Baraliakos X.
Bautista-Molano W.
Chiowchanwisawakit P.
Dagfinrud H.
Fallon L.
Garrido-Cumbrera M.
Gensler L.
Elzorkany B.K.
Haroon N.
Kwan Y.H.
MacHado P.M.
Maksymowych W.
Molto A.
De Peyrecave N.
Poddubnyy D.
Protopopov M.
Ramiro S.
Song I.H.
Van Weely S.
Van Der Heijde D.
Author's Affiliation
Siriraj Hospital
AbbVie
Fundacion Santa Fe de Bogota
Diakonhjemmet Sykehus
UCB S.A.
Universidad de Sevilla
UCSF School of Medicine
Northwick Park Hospital
Rheumazentrum Ruhrgebiet
Hospital Universitario La Paz
Charité – Universitätsmedizin Berlin
University College London Hospitals NHS Foundation Trust
University College London
AP-HP Assistance Publique - Hopitaux de Paris
University of Alberta, Faculty of Medicine and Dentistry
Universiteit Maastricht
National University of Singapore
Leids Universitair Medisch Centrum
University Health Network University of Toronto
Swedish Medical Center, Seattle
Cairo University
Pfizer Inc.
IdiPAZ
Axial Spondyloarthritis International Federation (ASIF)
Zuyderland Hospital
Amsterdam Rheumatology Center
Zuyderland Medical Center
AbbVie
Fundacion Santa Fe de Bogota
Diakonhjemmet Sykehus
UCB S.A.
Universidad de Sevilla
UCSF School of Medicine
Northwick Park Hospital
Rheumazentrum Ruhrgebiet
Hospital Universitario La Paz
Charité – Universitätsmedizin Berlin
University College London Hospitals NHS Foundation Trust
University College London
AP-HP Assistance Publique - Hopitaux de Paris
University of Alberta, Faculty of Medicine and Dentistry
Universiteit Maastricht
National University of Singapore
Leids Universitair Medisch Centrum
University Health Network University of Toronto
Swedish Medical Center, Seattle
Cairo University
Pfizer Inc.
IdiPAZ
Axial Spondyloarthritis International Federation (ASIF)
Zuyderland Hospital
Amsterdam Rheumatology Center
Zuyderland Medical Center
Other Contributor(s)
Abstract
Objectives To define the instruments for the Assessment of SpondyloArthritis international Society-Outcomes Measures in Rheumatology (ASAS-OMERACT) core domain set for axial spondyloarthritis (axSpA). Methods An international working group representing key stakeholders selected the core outcome instruments following a predefined process: (1) identifying candidate instruments using a systematic literature review; (2) reducing the list of candidate instruments by the working group, (3) assessing the instruments' psychometric properties following OMERACT filter 2.2, (4) selection of the core instruments by the working group and (5) voting and endorsement by ASAS. Results The updated core set for axSpA includes seven instruments for the domains that are mandatory for all trials: Ankylosing Spondylitis Disease Activity Score and Numerical Rate Scale (NRS) patient global assessment of disease activity, NRS total back pain, average NRS of duration and severity of morning stiffness, NRS fatigue, Bath Ankylosing Spondylitis Function Index and ASAS Health Index. There are 9 additional instruments considered mandatory for disease-modifying antirheumatic drugs (DMARDs) trials: MRI activity Spondyloarthritis Research Consortium of Canada (SPARCC) sacroiliac joints and SPARCC spine, uveitis, inflammatory bowel disease and psoriasis assessed as recommended by ASAS, 44 swollen joint count, Maastricht Ankylosing Spondylitis Enthesitis Score, dactylitis count and modified Stoke Ankylosing Spondylitis Spinal Score. The imaging outcomes are considered mandatory to be included in at least one trial for a drug tested for properties of DMARD. Furthermore, 11 additional instruments were also endorsed by ASAS, which can be used in axSpA trials on top of the core instruments. Conclusions The selection of the instruments for the ASAS-OMERACT core domain set completes the update of the core outcome set for axSpA, which should be used in all trials.